Cargando…

Efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with S-1 in 17 advanced gastric cancer patients with poor performance status

BACKGROUND: To evaluate the efficacy and safety of liposome-paclitaxel (L-PTX)/L-PTX plus S-1 in advanced gastric cancer patients with poor performance status (PS). METHODS: We performed this retrospective study on 17 advanced gastric cancer patients with poor PS [rated as ≥2 based on the Eastern Co...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Runhong, Shen, Zhu, Yu, Na, Xu, Jianhao, Yuan, Xuya, Ni, Liwei, Long, Yuming, Tao, Jialong, Zhang, Yusong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798635/
https://www.ncbi.nlm.nih.gov/pubmed/35116918
http://dx.doi.org/10.21037/tcr.2019.08.17
_version_ 1784641856028540928
author Wu, Runhong
Shen, Zhu
Yu, Na
Xu, Jianhao
Yuan, Xuya
Ni, Liwei
Long, Yuming
Tao, Jialong
Zhang, Yusong
author_facet Wu, Runhong
Shen, Zhu
Yu, Na
Xu, Jianhao
Yuan, Xuya
Ni, Liwei
Long, Yuming
Tao, Jialong
Zhang, Yusong
author_sort Wu, Runhong
collection PubMed
description BACKGROUND: To evaluate the efficacy and safety of liposome-paclitaxel (L-PTX)/L-PTX plus S-1 in advanced gastric cancer patients with poor performance status (PS). METHODS: We performed this retrospective study on 17 advanced gastric cancer patients with poor PS [rated as ≥2 based on the Eastern Cooperative Oncology Group (ECOG) scale] who underwent the following chemotherapy regimen: (I) L-PTX single-agent: L-PTX 60–80 mg/m(2) given on days 1 and 8, in a 21-day cycle; (II) timed sequential (TS) regimen: L-PTX 60–80 mg/m(2) given on days 1 and 8. S-1, 40–60 mg/m(2) twice a day on days 1–14, in a 21-day cycle. Initially, some patients could not tolerate the 2-drug combination chemotherapy regimen, only L-PTX single-agent was given. After the patient’s physical condition was improved, plus S-1 was also given. RESULTS: A total of 17 patients were studied. No complete response (CR) or partial response (PR) were observed in six patients, accounting for 35.29% (6/17). Stable disease (SD) was observed in five patients, accounting for 29.41% (5/17), and progressive disease (PD) in 6, accounting for 35.29% (6/17). The objective response and disease control rates were 35.29% (6/17) and 64.71% (11/17), respectively. The median progression-free survival (PFS) and median overall survival (OS) were 6.50 months [95% confidence interval (CI): 4.81–8.20] and 13.00 months (95% CI: 0.00–33.65), respectively. The most common hematological toxicities were neutropenia and anemia. CONCLUSIONS: L-PTX/L-PTX plus S-1 in the treatment of advanced gastric cancer patients with poor PS can prolong the patients’ PFS and OS, and the toxicity is tolerable.
format Online
Article
Text
id pubmed-8798635
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87986352022-02-02 Efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with S-1 in 17 advanced gastric cancer patients with poor performance status Wu, Runhong Shen, Zhu Yu, Na Xu, Jianhao Yuan, Xuya Ni, Liwei Long, Yuming Tao, Jialong Zhang, Yusong Transl Cancer Res Original Article BACKGROUND: To evaluate the efficacy and safety of liposome-paclitaxel (L-PTX)/L-PTX plus S-1 in advanced gastric cancer patients with poor performance status (PS). METHODS: We performed this retrospective study on 17 advanced gastric cancer patients with poor PS [rated as ≥2 based on the Eastern Cooperative Oncology Group (ECOG) scale] who underwent the following chemotherapy regimen: (I) L-PTX single-agent: L-PTX 60–80 mg/m(2) given on days 1 and 8, in a 21-day cycle; (II) timed sequential (TS) regimen: L-PTX 60–80 mg/m(2) given on days 1 and 8. S-1, 40–60 mg/m(2) twice a day on days 1–14, in a 21-day cycle. Initially, some patients could not tolerate the 2-drug combination chemotherapy regimen, only L-PTX single-agent was given. After the patient’s physical condition was improved, plus S-1 was also given. RESULTS: A total of 17 patients were studied. No complete response (CR) or partial response (PR) were observed in six patients, accounting for 35.29% (6/17). Stable disease (SD) was observed in five patients, accounting for 29.41% (5/17), and progressive disease (PD) in 6, accounting for 35.29% (6/17). The objective response and disease control rates were 35.29% (6/17) and 64.71% (11/17), respectively. The median progression-free survival (PFS) and median overall survival (OS) were 6.50 months [95% confidence interval (CI): 4.81–8.20] and 13.00 months (95% CI: 0.00–33.65), respectively. The most common hematological toxicities were neutropenia and anemia. CONCLUSIONS: L-PTX/L-PTX plus S-1 in the treatment of advanced gastric cancer patients with poor PS can prolong the patients’ PFS and OS, and the toxicity is tolerable. AME Publishing Company 2019-09 /pmc/articles/PMC8798635/ /pubmed/35116918 http://dx.doi.org/10.21037/tcr.2019.08.17 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Original Article
Wu, Runhong
Shen, Zhu
Yu, Na
Xu, Jianhao
Yuan, Xuya
Ni, Liwei
Long, Yuming
Tao, Jialong
Zhang, Yusong
Efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with S-1 in 17 advanced gastric cancer patients with poor performance status
title Efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with S-1 in 17 advanced gastric cancer patients with poor performance status
title_full Efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with S-1 in 17 advanced gastric cancer patients with poor performance status
title_fullStr Efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with S-1 in 17 advanced gastric cancer patients with poor performance status
title_full_unstemmed Efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with S-1 in 17 advanced gastric cancer patients with poor performance status
title_short Efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with S-1 in 17 advanced gastric cancer patients with poor performance status
title_sort efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with s-1 in 17 advanced gastric cancer patients with poor performance status
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798635/
https://www.ncbi.nlm.nih.gov/pubmed/35116918
http://dx.doi.org/10.21037/tcr.2019.08.17
work_keys_str_mv AT wurunhong efficacyandsafetyofliposomepaclitaxelliposomepaclitaxelcombinedwiths1in17advancedgastriccancerpatientswithpoorperformancestatus
AT shenzhu efficacyandsafetyofliposomepaclitaxelliposomepaclitaxelcombinedwiths1in17advancedgastriccancerpatientswithpoorperformancestatus
AT yuna efficacyandsafetyofliposomepaclitaxelliposomepaclitaxelcombinedwiths1in17advancedgastriccancerpatientswithpoorperformancestatus
AT xujianhao efficacyandsafetyofliposomepaclitaxelliposomepaclitaxelcombinedwiths1in17advancedgastriccancerpatientswithpoorperformancestatus
AT yuanxuya efficacyandsafetyofliposomepaclitaxelliposomepaclitaxelcombinedwiths1in17advancedgastriccancerpatientswithpoorperformancestatus
AT niliwei efficacyandsafetyofliposomepaclitaxelliposomepaclitaxelcombinedwiths1in17advancedgastriccancerpatientswithpoorperformancestatus
AT longyuming efficacyandsafetyofliposomepaclitaxelliposomepaclitaxelcombinedwiths1in17advancedgastriccancerpatientswithpoorperformancestatus
AT taojialong efficacyandsafetyofliposomepaclitaxelliposomepaclitaxelcombinedwiths1in17advancedgastriccancerpatientswithpoorperformancestatus
AT zhangyusong efficacyandsafetyofliposomepaclitaxelliposomepaclitaxelcombinedwiths1in17advancedgastriccancerpatientswithpoorperformancestatus